Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Post Doctoral Fellow, University Of Virginia
1981
Post Doctoral Fellow, Louisiana State University School of Medicine
1979
Residency, Louisiana State University School of Medicine
1977
Residency, Indiana University
1974
Doctor of Medicine, Tufts University
1972
Bachelor of Arts, Cornell University
1969
Fingerprint
Dive into the research topics where Richard Greenberg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
Candida 301: An Interventional Efficacy and Safety Phase 3 Double-Blind 2-Arm Study to Investigate IV Followed by Oral Fosmanogepix Compared with IV Caspofungin Followed by Oral Fluconazole in Adult Participants with Candidemia and/or Invasive Candidiasis
Greenberg, R. (PI)
Basilea Pharmaceutica International Ltd Allschwil
12/10/24 → 12/9/26
Project: Research project
-
A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (#50 years of age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses an
Greenberg, R. (PI)
10/31/23 → 10/31/25
Project: Research project
-
COVID-19: BNT-162: An Exploratory Phase 1, Randomized, Observer-Blind, Active-Controlled Dose Escalation Trial Evaluating the Safety, Tolerability and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Health
Greenberg, R. (PI) & Simmons, C. (CoI)
1/6/23 → 1/11/26
Project: Research project
-
A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant whe
Greenberg, R. (PI)
3/3/22 → 10/12/25
Project: Research project
-
Covid 19: SCOPE: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults Aged 18 Years and Older
Greenberg, R. (PI), Caudill, T. (CoI), Kern, P. (CoI) & Simmons, C. (CoI)
Janssen Vaccines and Prevention BV
9/25/20 → 5/5/25
Project: Research project
-
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
Greenberg, R. N., Schmidt, D., Reichhardt, D., Roesch, S., Vidojkovic, S., Maclennan, J., Chen, L. M., Gruenert, R., Kreusel, C., Weidenthaler, H., Meyer, T. P. H. & Chaplin, P. J., 2024, In: Human Vaccines and Immunotherapeutics. 20, 1, 2384189.Research output: Contribution to journal › Article › peer-review
Open Access -
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
the CoVPN 3006 Study Team, Nov 1 2023, In: Open Forum Infectious Diseases. 10, 11, ofad511.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study
Thompson, G. R., Garcia-Diaz, J., Miceli, M. H., Nguyen, M. H., Ostrosky-Zeichner, L., Young, J. A. H., Fisher, C. E., Clark, N. M., Greenberg, R. N., Spec, A., Kovanda, L., Croos-Dabrera, R. & Kontoyiannis, D. P., Feb 2022, In: Mycoses. 65, 2, p. 186-198 13 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations -
Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))
Gwag, T., Meng, Z., Sui, Y., Helsley, R. N., Park, S. H., Wang, S., Greenberg, R. N. & Zhou, C., Apr 2021, In: Journal of Hepatology. 74, 4, p. 1003-1004 2 p.Research output: Contribution to journal › Comment/debate
Open Access -
A Paradigm Shift Has Begun: Diarrheal Disease Takes a New Form
Ribes, J. A., Arora, V. & Greenberg, R. N., Oct 15 2019, In: Clinical Infectious Diseases. 69, 9, p. 1553-1554 2 p.Research output: Contribution to journal › Comment/debate